G-CSF: filgrastim, lenograstim and biosimilars

Bibliography

• Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer 2010;10:425-34
   PubMed Web of Science ®Google Scholar
• Welte K, Platzer E, Lu I, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 1985;82:1526-30
   PubMed Web of Science ®Google Scholar
• Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colonystimulating factor: effects on normal and leukemic myeloid cells. Science 1986;232:61-5
   PubMed Web of Science ®Google Scholar
• Nomura H, Imazeki I, Oheda M, et al. Purification and characterization of human granulocyte colony-stimulating factor (G-CSF). EMBO J 1986;5:871-6
   PubMed Web of Science ®Google Scholar
• Nagata S, Tsuchiya M, Asano S, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 1986;319:415-18
   PubMed Web of Science ®Google Scholar
• Fukunaga R, Ishizaka-Ikeda E, Nagata S. Purification and characterization of thereceptor for murine granulocyte-colony-stimulating factor. J Biol Chem 1990;265:14008-15
   PubMed Web of Science ®Google Scholar
• Tanaka H, Tanaka Y, Shinagawa K, et al. Three types of recombinant human granulocyte colony-stimulating factor have equivalent biological activities in monkeys. Cytokine 1997;9:360-9
   PubMed Web of Science ®Google Scholar
• Platzer E, Welte K, Gabrilove JL, et al. Biological activities of a human pluripotent hematopoietic colony stimulating factor on normal and leukemic cells. J Exp Med 1985;162:1788-801
   PubMed Web of Science ®Google Scholar
• Strife A, Lambek C, Wisniewski D, et al. Activities of four purified growth factors on highly enriched human hematopoietic progenitor cells. Blood 1987;69:1508-23
   PubMed Web of Science ®Google Scholar
• Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994;84:1737-46
   PubMed Web of Science ®Google Scholar
• de Koning JP, Dong F, Smith L, et al. The membrane-distal cytoplasmic region of human granulocyte colony-stimulating factor receptor is required for STAT3 but not STAT1 homodimer formation. Blood 1996;87:1335-42
   PubMedGoogle Scholar
• Skokowa J, Cario G, Uenalan M, et al. LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med 2006;12:1191-7
   PubMed Web of Science ®Google Scholar
• Skokowa J, Lan D, Thakur BK, et al. NAMPT is essential for the G-CSF induced myeloid differentiation via NAD+-sirtuin-1-dependent pathway. Nat Med 2009;15:151-8
   PubMed Web of Science ®Google Scholar
• Skokowa J, Klimiankou M, Klimenkova O, et al. Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis. Nat Med 2012;18:1550-9
   PubMed Web of Science ®Google Scholar
• Welte K, Bonilla MA, Gillio AP, et al. Recombinant human granulocyte colonystimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987;165:941-8
   PubMed Web of Science ®Google Scholar
• Gillio AP, Bonilla MA, Potter GK, et al. Effects of recombinant human granulocyte colony stimulating factor on hematopoietic reconstitution after autologous bone marrow transplantation in primates. Transplant Proc 1987;19:153
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414-22
   PubMed Web of Science ®Google Scholar
• Bronchud MH, Scarfe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987;56:809-13
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70
   PubMed Web of Science ®Google Scholar
• Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996;88:1907-29
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther 2009;31:1092-104
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Touw IT. Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993;81:281-92
   PubMed Web of Science ®Google Scholar
• Ohno R, Naoe T, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994;83:2015-19
   PubMedGoogle Scholar
• Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;12:671-8
   PubMed Web of Science ®Google Scholar
• Giralt S, Escudier S, Kantarjian H, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 1993;329:757-61
   PubMed Web of Science ®Google Scholar
• Welte K, Reiter A, Mempel K, et al. A randomized phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 1996;87:3143-50
   PubMed Web of Science ®Google Scholar
• Sasse EC, Sasse AD, Brandalise SR, et al. Colony-stimulating factors for prevention of myelosuppressive therapy-induced febrile neutropenia in children with acute lymphoblastic leukemia. Cochrane Database Syst Rev 2005;(3):CD004139
   Google Scholar
• Ehlers S, Herbst C, Zimmermann M, et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol 2010;28:2591-7
   PubMed Web of Science ®Google Scholar
• Pabst T, Vellenga E, van Putten W, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German AML Study Group (AMLSG); Swiss Collaborative Group for Clinical Cancer Research (SAKK). Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012;119:5367-73
   PubMed Web of Science ®Google Scholar
• Taylor KM, Jagganath S, Spitzer G, et al. Recombinant human granulocyte colonystimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin‘s disease. J Clin Oncol 1989;7:1791-9
   PubMed Web of Science ®Google Scholar
• Sheridan WP, Morstyn G, Wolf M, et al. Granulocyte colony stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989;2:891-5
   PubMed Web of Science ®Google Scholar
• Dührsen U, Villeval JL, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-81
   PubMed Web of Science ®Google Scholar
• Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640-4
   PubMed Web of Science ®Google Scholar
• De Luca E, Sheridan WP, Watson D, et al. Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. Br J Cancer 1992;66:893-9
   PubMed Web of Science ®Google Scholar
• Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood progenitor mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993;81:3158-63
   PubMed Web of Science ®Google Scholar
• Kim HK, De La Luz Sierra M, Williams CK, et al.F down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood 2006;108:812-20
   PubMed Web of Science ®Google Scholar
• Ringdén O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004;22:416-23
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Loberiza FR Jr, Ringden O, et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006;107:1712-16
   PubMed Web of Science ®Google Scholar
• Martin PJ. Choosing between GVHD and delayed engraftment. Nat Med 2009;15:363-4
   PubMed Web of Science ®Google Scholar
• Ho VT, Mirza NQ, del Junco D, et al. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation a meta-analysis. Bone Marrow Transplant 2003;32:771-5
   PubMed Web of Science ®Google Scholar
• Bonilla MA, Gillio AP, Ruggeiro M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 1989;320:1574-80
   PubMed Web of Science ®Google Scholar
• Welte K, Zeidler C, Reiter A, et al. Differential effects of granulocyte-macrophage colony stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 1990;75:1056-63
   PubMed Web of Science ®Google Scholar
• Dale DC, Bonilla MA, Davis MS, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severechronic neutropenia. Blood 1993;81:2496-502
   PubMed Web of Science ®Google Scholar
• Bonilla MA, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinanthuman granulocyte colony stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 1994;88:723-30
   PubMed Web of Science ®Google Scholar
• Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. Semin Hematol 2006;43:189-95
   PubMed Web of Science ®Google Scholar
• Zeidler C, Germeshausen M, Klein C, Welte K. Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia. Br J Haematol 2009;144:459-67
   PubMed Web of Science ®Google Scholar
• Rosenberg PS, Zeidler C, Bolyard AA, et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol 2010;150:196-9
   PubMed Web of Science ®Google Scholar
• Skokowa J, Steinemann D, Katsman-Kuipers J, et al. Cooperativity of RUNX1 and CSF3R Mutations in the Development of Leukemia in severe congenital Neutropenia: a Unique Pathway in Myeloid Leukemogenesis. Blood 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol 2012;7(Suppl 1):29-34
   PubMedGoogle Scholar
• Gravel P, Naik A, Le Cotonnec J-Y. Biosimilar rhG-CSFs: how similar are they? Target Oncol 2012;7(Suppl 1):3-16
   PubMedGoogle Scholar
• Waller CF, Bronchud M, Mair S, Challand R. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 2010;89:927-33
   Web of Science ®Google Scholar
• Waller CF, Bronchud M, Mair S, Challand R. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 2010;89:971-8
   PubMed Web of Science ®Google Scholar
• Waller CF, Semiglazov VF, Tjulandin S, et al. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 2010;33:504-11
   PubMedGoogle Scholar
• Gatzemeier U, Ciuleanu T, Dediu M, et al. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009;4:736-40
   PubMed Web of Science ®Google Scholar
• Engert A, Griskevicius L, Zyuzgin Y, et al. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009;50:374-9
   PubMed Web of Science ®Google Scholar
• Lefrere F, Brignier AC, Elie C, et al. First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. Adv Ther 2011;28:304-10
   PubMed Web of Science ®Google Scholar
• Ianotto JC, Tempescul A, Yan X, et al. Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients. Bone Marrow Transplant 2012;47:874-6
   PubMed Web of Science ®Google Scholar
• Shaw BE, Confer DL, Hwang WY, et al. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica 2011;96:942-7
   PubMed Web of Science ®Google Scholar
• Gascón P, Tesch H, Verpoort K, et al. Clinical experience with Zarzio® in Europe: what have we learned? Support Care Cancer 2013;21:2925-32
   PubMed Web of Science ®Google Scholar
• Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm 2012;18:171-9
   PubMedGoogle Scholar